CIFFREO Trial of Potential DMD Gene Therapy Delayed in US

CIFFREO Trial of Potential DMD Gene Therapy Delayed in US

293684

CIFFREO Trial of Potential DMD Gene Therapy Delayed in US

Pfizer has announced a delay in opening U.S. sites for its Phase 3 clinical trial CIFFREO, evaluating the investigational gene therapy PF-06939926 in boys with Duchenne muscular dystrophy (DMD). The delay is caused by questions from the U.S. Food and Drug Administration (FDA) regarding the company’s investigational new drug application, which was submitted to ask for permission to run the trial.  Specifically, the questions focused on technical aspects of the company’s potency tests, which are…

You must be logged in to read/download the full post.